
Ipamorelin
COA pending
A selective ghrelin-receptor agonist studied in growth-hormone release research.

Growth Hormone
A combined GHRH analog and ghrelin-receptor agonist preparation used in secretagogue research.
Select size
Quantity
Total
$79.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
COA pending. The certificate for this lot will be uploaded to our COA library as soon as we have it.
Have a question?
For research use only. Not for human consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
A co-formulation of two compounds that act on different receptors: CJC-1295, a GHRH-receptor analog developed by ConjuChem, and ipamorelin, a selective growth-hormone secretagogue described by Novo Nordisk researchers in 1998. The pairing is a supplier formulation; the combination itself has no independent discovery history or characterisation.
The interest in pairing these two is mechanistic rather than empirical: they engage two separate receptor systems on the somatotroph — the GHRH receptor and the ghrelin/growth-hormone-secretagogue receptor (GHS-R1a). Each is characterised independently in the literature cited under its own entry. No peer-reviewed work characterises this specific blend as a single entity. Neither constituent is FDA-approved for human use, and both classes appear on the WADA Prohibited List.
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Summaries of published literature for research reference only. Not a claim about any product’s effect.
Batch releases & restocks
Every certificate is published and available for review. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.

COA pending
A selective ghrelin-receptor agonist studied in growth-hormone release research.

COA pending
A GHRH(1-29) analog examined in endocrine and pituitary-signalling research.

COA published
A growth-hormone-releasing factor analog examined in endocrine-pathway research models.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.